Bibliography
- Rosenblum LT , ChoykePL, KobayashiH. Quantitative and specific molecular imaging of cancer with labeled engineered monoclonal antibody fragments. Therapeutic Delivery2(3), 345–358 (2011).
- Goldmacher VS , KovtunYV. Antibody–drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Therapeutic Delivery2(3), 397–416 (2011).
- The Future of Monoclonal Antibodies – Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis. GBI Research. 1 December 2009.
- Han C , ZhouH. Monoclonal antibodies: interspecies scaling with minimal preclinical information. Therapeutic Delivery2(3), 359–368 (2011).
- Beckman RA , von Roemling R, Acott AM. Monoclonal antibody dose determination and biodistribution into solid tumors. Therapeutic Delivery2(3), 333–344 (2011).
- Lee JW , KelleyM. Quality assessment of bioanalytical quantification of monoclonal antibody drugs. Therapeutic Delivery2(3), 383–396 (2011).
- Grimstein C , BaiJFP. Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. Therapeutic Delivery2(3), 369–381 (2011).
Websites
- Drugs@FDA. www.accessdata.fda.gov/scripts/cder/drugsatfda (Accessed 8January2011).
- Marketresearch.com. www.marketsandmarkets.com/Market-Reports/monoclonal-antibodies-261.html (Accessed 2January2011).